Drug intelligence / Profile preview

NC318 + docetaxel

Development stage: Preclinical
Lead developer: NextCure
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

NC318 + docetaxel is an experimental combination therapy consisting of NC318, a monoclonal antibody targeting Siglec-15, and docetaxel, a taxoid antineoplastic chemotherapy agent. Docetaxel acts by stabilizing microtubules and inhibiting their depolymerization, thereby preventing cell division and promoting apoptosis in cancer cells[1]. NC318 is under investigation as an immunotherapy that blocks Siglec-15, a suppressive molecule in the tumor microenvironment. Combination with docetaxel is being explored to enhance anti-tumor immune responses in advanced cancer, notably non-small cell lung cancer (NSCLC). This combination is hypothesized to provide additive or synergistic anti-cancer effects through cytotoxic action and immune checkpoint modulation.

Other names: docetaxelNC318 + docetaxel

Targets

SIGLEC15 (Sialic acid-binding immunoglobulin-like lectin 15)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on NC318 + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC318 + docetaxel.

Explore the full profile